BMC Cancer: Efficacy and safety of cisplatin plus etoposide (EP) vs carboplatin plus etoposide (EC) in the treatment of extensive-stage SCLC

Small cell lung cancer (SCLC) is a highly aggressive type of lung cancer, accounting for approximately 15% of all newly diagnosed lung cancer cases

Small cell lung cancer (SCLC) is a highly aggressive type of lung cancer, accounting for approximately 15% of all newly diagnosed lung cancer cases

Among the 1305 patients included, most were male (n = 928, 68.

Among the 1305 patients included, most were male (n = 928, 68.

After excluding 4 patients lacking survival data, 1301 patients were included for survival analysis

PFS and OS

Multivariate analysis showed that female patients (HR = 0.

Multivariate analysis showed that female patients (HR = 0.

After adjusting for age, gender, body mass index, ECOG PS and other factors, the EP program is for overweight and obese patients (BMI ≥25 kg/m ² ) PFS (hazard ratio [HR] = 0.

In the safety analysis, patients who received EC treatment experienced grade 3 AEs (n = 599, 74.

In summary, studies have shown that there is no significant difference between EC and EP regimens in the first-line treatment of patients with extensive-stage SCLC

Original source:

Original source:

Jiang S, Huang L, Zhen H, Jin P, Wang J, Hu Z.

Jiang S, Huang L, Zhen H, Jin P, Wang J, Hu Z.
Carboplatin versus cisplatin in combination with etoposide in the first-line treatment of small cell lung cancer: a pooled analysis.
BMC Cancer.
2021 Dec 7;21( 1):1308.
doi: 10.
1186/s12885-021-09034-6.
PMID: 34876060; PMCID: PMC8650295.


Leave a message here